eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
.
.
.
. would identify hospitals that are best positioned to treat strokes and establish protocols for emergency responders handling stroke patients.
. 0
.